Stock ALOPM ONCODESIGN PRECISION MEDICINE
Add to a list
To use this feature you must be a member
Log inSign up

News Oncodesign Precision Medicine

Equities

ALOPM

FR001400CM63

Real-time Euronext Paris
Other stock markets
 04:38:24 24/05/2024 pm IST 		5-day change 1st Jan Change
1.23 EUR -1.20% Intraday chart for Oncodesign Precision Medicine -5.38% -32.04%
15/05 Oncodesign Precision Medicine and Navigo Proteins GmbH Sign A Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents CI
25/01 Oncodesign Precision Medicine: fundraising on the horizon CF

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oncodesign Precision Medicine and Navigo Proteins GmbH Sign a Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents
BU
Oncodesign Precision Medicine and Navigo Proteins GmbH Sign A Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents
CI
Degroof Petercam Initiates Coverage of Oncodesign Precision Medicine
BU
Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101
BU
OPM Publishes Its Annual Results for 2023 and Provides an Update on Its Clinical Developments
BU
Oncodesign Precision Medicine : OPM publishes its annual results for 2023 and provides an update on its clinical developments
PU
Oncodesign Precision Medicine: fundraising on the horizon
CF
Oncodesign Precision Medicine Receives ERDF Fund Totalling ?2.1 Million for its Comete Program
CI
Eurazeo acquires a stake in Oncodesign Services
CF
Oncodesign Precision Medicine Société anonyme announced that it has received ?22 million in funding from Eurazeo SE and other investors
CI
Oncodesign Precision Medicine Société anonyme acquired Zobio B.v.
CI
Oncodesign Precision Medicine Obtains EUR6 Million Loan from Regional Banks
MT
Oncodesign Precision Medicine Announces Positive Interim Results of Its Phase 1 Study Evaluating OPM-101 in Healthy Volunteers
CI
Oncodesign Precision Medicine Société Anonyme Approves the Nomination of Florence Dupré to the Board of Directors
CI
Oncodesign Precision Medicine : OPM announces its 2022 results
PU
Oncodesign launches clinical trial in IBD
CF
Oncodesign Precision Medicine : OPM announces the initiation of Phase I of ODS-101
PU
Oncodesign Precision Medicine Announces Initiation of Phase I of its RIPK2 Inhibitor ODS-101, aNew Therapeutic Agent for IBD
CI
Edmond de Rothschild Equity Strategies Management III S.à.r.l acquired 61.58% stakes in Oncodesign Precision Medicine Société anonyme from Philippe Genne and other managers and minority shareholder.
CI
Oncodesign Precision Medicine to List Directly on Euronext Access + Paris
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALOPM Stock
  4. News Oncodesign Precision Medicine